12/18/2025
This is the safest and easiest treatment for peanut allergy, and it looks like it works too!
DBV Technologies has announced positive topline results from the Phase 3 VITESSE clinical trial evaluating the investigational VIASKIN® Peanut patch in children ages 4–7 living with peanut allergy.
The study met its primary endpoint, with 46.6% of children using the patch meeting treatment response criteria after 12 months, compared to 14.8% in the placebo group. Children in the treatment group were able to tolerate significantly greater amounts of peanut protein, indicating increased protection against accidental exposure. Safety results were consistent with prior studies, with most side effects reported as mild to moderate skin reactions at the patch site, and treatment-related anaphylaxis reported as rare.
While the VIASKIN® Peanut patch is still investigational and not yet approved by the FDA, progress like this helps bring the food allergy community closer to additional, non-invasive treatment options.
We are deeply grateful to every family and researcher helping shape the future of food allergy care.